Cytek Biosciences, Inc. (NASDAQ:CTKB) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Paul Goodson - Investor Relations Wenbin Jiang - Chief Executive Officer William McCombe - Chief Financial Officer Conference Call Participants Operator Thank you for standing by. My name is Luella, and I will be your conference operator today. At this time, I would like to welcome everyone to Cytek Biosciences' Second Quarter 2024 Earnings Conference Call. [Operator Instructions] I would no ...

Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -166.67%. A quarter ago, it was expected that this company would post a loss of $0.05 per share when it actually produced a loss of $0.05, delivering no surprise. Over the last four quarters, the company has s ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q _______________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001 ...

Exhibit 99.1 Cytek Biosciences Reports Second Quarter 2024 Financial Results FREMONT, Calif., August 6, 2024 (GLOBE NEWSWIRE) — Cytek® Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights • Total revenue for the second quarter of 2024 was $46.6 million, representing a 4% increase sequentially over the first quarter of 2024 and a 6% decrease over the second q ...

Core Insights - Cytek Biosciences, Inc. has launched the SpectroPanel tool, which automates the panel design process, significantly reducing the time required from days or weeks to minutes, thereby enhancing user experience and adoption of flow cytometry technology [4][8] - The Cytek Cloud platform now supports over 11,000 users and integrates various tools for flow cytometry research, including panel design, experiment setup, and data acquisition [1][9] - The company aims to expand Cytek Cloud's capabilities further, focusing on enhanced data management, sharing, and analysis features in response to user needs [4][8] Company Overview - Cytek Biosciences specializes in cell analysis solutions, utilizing its patented Full Spectrum Profiling™ (FSP™) technology to provide high-resolution and high-sensitivity analysis tools [4] - The company's product offerings include core instruments like the Cytek Aurora™ and Northern Lights™ systems, as well as reagents and software, creating a comprehensive suite for customers [4] - Cytek is headquartered in Fremont, California, with a global presence through offices and distribution channels [4] Product Features - The SpectroPanel tool is designed to optimize fluorochrome assignment to markers, streamlining the panel design process for researchers [3] - Cytek Cloud features an easy-to-use panel wizard that allows users to search, modify, and share pre-designed panels, facilitating collaboration and efficiency in research [9] - The platform supports a wide range of applications, including immunology, oncology, infectious diseases, and inflammatory diseases, accelerating the time to insight for researchers [9]

Optimized for Cytek's Full Spectrum Profiling™ (FSP™) technology, the SpectroPanel tool automates the assignment of fluorochromes to markers, removing the labor-intensive manual process. This allows scientists to jumpstart their panel design process. Cytek Cloud consists of a suite of integrated, online software tools that streamline workflows – combining all spectral panel design tools in one place and allowing users to prepare experiments remotely. Cytek Cloud accelerates the time to insight for a wide ra ...

The program does not obligate the Company to acquire any particular amount of common stock and the program may be modified or suspended at any time at the Company's discretion. Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc. time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek's forward-looking statements. Although Cytek believes ...

Core Insights - Cytek Biosciences, Inc. has received NMPA approval for its 1-laser and 2-laser 6-color TBNK reagent cocktails for clinical diagnostic use in China, marking a significant milestone for the company [1][3] Group 1: Product and Technology - The TBNK reagents are designed for clinical use to assess and monitor immune system status, aiding in the diagnosis of various immune-related conditions such as immunodeficiencies, autoimmune diseases, infectious diseases, and cancers [2] - The TBNK assay is the first clinical 1-laser based 6-color assay supported by Full Spectrum Profiling™ (FSP™) technology, which enhances the capability of cell analysis systems [1][3] - The Cytek Northern Lights-Clinical (NL-CLC) cell analysis systems utilize an on-board volumetric meter for absolute cell counts, reducing testing costs compared to traditional methods [3] Group 2: Market Impact and Strategy - The NMPA clearance enhances Cytek's market presence in China and opens new opportunities, strengthening its competitive advantage in the cell analysis market [3] - Cytek aims to continue seeking regulatory approvals in additional geographies to broaden the availability of its cell analysis solutions for clinical use [3][4] Group 3: Company Overview - Cytek Biosciences is a leading company in cell analysis solutions, utilizing patented Full Spectrum Profiling™ technology to deliver high-resolution and high-sensitivity cell analysis tools [4] - The company's product portfolio includes core instruments like the Cytek Aurora™ and Northern Lights™ systems, as well as various reagents and software solutions [4]

FREMONT, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, officially announced its Enhanced Small Particle (ESP™) Detection Option for its flagship Cytek Aurora™ and Cytek Northern Lights™ cell analysis systems. With this optional upgrade, these systems show superior sensitivity and resolution of subcellular materials, including extracellular vesicles (EVs), while maintaining high resolution and high parameter capabilities for ...

FREMONT, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, officially announced its Enhanced Small Particle (ESP™) Detection Option for its flagship Cytek Aurora™ and Cytek Northern Lights™ cell analysis systems. With this optional upgrade, these systems show superior sensitivity and resolution of subcellular materials, including extracellular vesicles (EVs), while maintaining high resolution and high parameter capabilities for ...